PreprintConcept PaperVersion 1Preserved in Portico This version is not peer-reviewed
Development and Evaluation of Novel Apomorphine and Quetiapine Combinational Formulation for Parkinson’s Disease in Rat: New Era (Possibilities) for Pre – Clinical Protocol Concept Review
Version 1
: Received: 7 May 2023 / Approved: 9 May 2023 / Online: 9 May 2023 (03:49:48 CEST)
How to cite:
Patel, M. Development and Evaluation of Novel Apomorphine and Quetiapine Combinational Formulation for Parkinson’s Disease in Rat: New Era (Possibilities) for Pre – Clinical Protocol Concept Review. Preprints2023, 2023050554. https://doi.org/10.20944/preprints202305.0554.v1
Patel, M. Development and Evaluation of Novel Apomorphine and Quetiapine Combinational Formulation for Parkinson’s Disease in Rat: New Era (Possibilities) for Pre – Clinical Protocol Concept Review. Preprints 2023, 2023050554. https://doi.org/10.20944/preprints202305.0554.v1
Patel, M. Development and Evaluation of Novel Apomorphine and Quetiapine Combinational Formulation for Parkinson’s Disease in Rat: New Era (Possibilities) for Pre – Clinical Protocol Concept Review. Preprints2023, 2023050554. https://doi.org/10.20944/preprints202305.0554.v1
APA Style
Patel, M. (2023). Development and Evaluation of Novel Apomorphine and Quetiapine Combinational Formulation for Parkinson’s Disease in Rat: New Era (Possibilities) for Pre – Clinical Protocol Concept Review. Preprints. https://doi.org/10.20944/preprints202305.0554.v1
Chicago/Turabian Style
Patel, M. 2023 "Development and Evaluation of Novel Apomorphine and Quetiapine Combinational Formulation for Parkinson’s Disease in Rat: New Era (Possibilities) for Pre – Clinical Protocol Concept Review" Preprints. https://doi.org/10.20944/preprints202305.0554.v1
Abstract
Parkinson's Disease (PD) is a neurodegenerative disorder that affects the motor system of the human body. Currently, the available treatments are limited and often have undesirable side effects. In this context, the aim of this study was to develop a novel combinational formulation of Apomorphine and Quetiapine and evaluate its efficacy in a rat model of PD. The formulation was prepared using the solvent evaporation technique and characterized for its physicochemical properties. The in-vitro drug release was evaluated using the Franz diffusion cell method, and the pharmacokinetics of the combination was studied in rats. The behavioural and biochemical parameters were evaluated in the rats using the Rotarod, pole test, and biochemical assays. The results showed that the developed formulation had satisfactory physicochemical properties and exhibited sustained drug release. The pharmacokinetic studies showed that the combination exhibited a longer residence time than the individual drugs. The behavioural and biochemical parameters showed that the combination was effective in improving motor function and reducing oxidative stress. In conclusion, the developed Apomorphine and Quetiapine combination formulation showed promising results in improving motor function and reducing oxidative stress in rat model of PD. Further studies are required to evaluate the safety and efficacy of the developed formulation in humans.
Keywords
Parkinson’s Disease; Pre-Clinical Protocol; Novel Combinational Formulation; In Vivo Model; In Vivo Study
Subject
Medicine and Pharmacology, Psychiatry and Mental Health
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
